Skip to main content
. 2022 Jun 16;146(3):265–275. doi: 10.1111/ane.13659

FIGURE 3.

FIGURE 3

Time to onset of treatment‐emergent adverse events: somnolence (A), dizziness (B), fatigue (C), and headache (D). CNB, cenobamate. The 52 weeks presented along the x‐axis include the pooled double‐blind titration and maintenance phases as well as the open‐label extension period